Marker Therapeutics Inc (MRKR)

[microcapbiotech]

OK, I admit, I'm confused. All talking about huCART19-IL18. Opinions anybody?
From Nov 2022: https://ashpublications.org/blood/article/140/Supplement%201/4612/491850/Interleukin-18-Secreting-Autologous-Anti-CD19-CAR
Out of 8 patients infused "Cytokine release syndrome (CRS) occurred in 4 (50%) pts: Grade (G)1 in 2, G2 in 1, G3 in 1 with median onset at 7.5 days (2-8) and median duration of 5.5 days (5-11); 2 pts required anti-cytokine therapy. Neurotoxicity occurred in 2 (25%) pts: 1 on day 20 lasting for 2 days (G1) and 1 on day 8 for 6 days (G2). Other non-hematologic G3 or higher adverse events at least possibly related to huCART19-IL18 included infections in 2 (25%), hypotension in 2 (25%), and AST elevation in 1 (12.5%) in the setting of CRS. There have been no study-related deaths."
"Conclusions: In this first-in-human study, huCART19-IL18 shows a manageable toxicity profile and encouraging early efficacy across all dose levels in heavily pretreated pts with CD19+ NHL including those who did not respond to prior 2nd generation CAR T-cell products. Enrollment continues at DL3."

From Dec 2022: https://www.pennmedicine.org/news/news-releases/2022/december/advance-in-re-treatment-with-car-t-therapy
"Among the first seven patients who received huCART19-IL18 – including those who previously did not respond to or relapsed following treatment with commercial CAR T cell therapies – all responded to the therapy (four patients had a complete response and three patients had a partial response). None of the four patients whose cancers completely responded to treatment at month three have seen their disease return, and all patients are alive at a median follow-up of eight months."
"Notably, with a three-day manufacturing time, huCART19-IL18 can be ready to administer more quickly than CAR T products with the typical manufacturing time of nine to 14 days, which is especially important for patients with aggressive, fast-growing disease."

From July 2023: https://www.onclive.com/view/hucart19-il8-proves-safe-and-elicits-durable-responses-in-car-t-pretreated-r-r-lymphoma
"huCART19-IL18 elicited an objective response rate of 82% (95% CI, 53%-97%) in this population (n = 11), which included a complete response rate of 55% and a partial response rate of 27%."

Is any of the above anything to be concerned about in relation to MRKR Multi-TAA?
I don't know if it's apples to apples or apples to oranges??